Aprea Therapeutics
Aprea focuses on the discovery and development of novel anticancer compounds reactivating the tumor suppressor protein p53.
Aprea Therapeutics has raised €5.0M across 1 funding round from 1 investor, most recently a Series C round in Jan 2019. Based in Stockholm, Sweden; founded 2003; active in Healthtech. Data as of 28 Oct 2026.
Total raised
€5.0M
€5,000,000
Funding rounds
1
Investors
1
distinct backers
Active since
2019-01
latest 2019-01
Funding by year
EUR raised per yearAprea Therapeutics — funding by year — interactive chart.
Data table
| Aprea Therapeutics — funding by year | |
|---|---|
| 2018 | €5.0M |
Signals
High confidenceRaise-next likelihood9
base rate 50% for Series C
- ▼ Dormant (no round in 3+ cohort gaps)
- ▼ Low backer re-investment
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2019-01-01 | Series C | €5.0M | Janus Henderson Investors | View deal → |